These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 18163895)

  • 1. Sixth nerve palsy post intravitreal bevacizumab for AMD: a new possibly causal relationship and complication?
    Park HJ; Guy J
    Binocul Vis Strabismus Q; 2007; 22(4):209. PubMed ID: 18163895
    [No Abstract]   [Full Text] [Related]  

  • 2. Isolated sixth nerve palsy after intravitreal bevacizumab injection.
    Cakmak HB; Toklu Y; Yorgun MA; Simşek S
    Strabismus; 2010 Mar; 18(1):18-20. PubMed ID: 20230202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Third nerve palsy following intravitreal anti-VEGF therapy for bilateral neovascular age-related macular degeneration.
    Micieli JA; Santiago P; Brent MH
    Acta Ophthalmol; 2011 Feb; 89(1):e99-100. PubMed ID: 19925526
    [No Abstract]   [Full Text] [Related]  

  • 4. Case of anterior uveitis after intravitreal injection of bevacizumab.
    Pieramici DJ; Avery RL; Castellarin AA; Nasir MA; Rabena M
    Retina; 2006 Sep; 26(7):841-2. PubMed ID: 16963867
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparing ranibizumab with bevacizumab.
    Biswas P; Sengupta S; Choudhary R; Home S; Paul A; Sinha S
    Ophthalmology; 2011 Mar; 118(3):600-600.e2. PubMed ID: 21376243
    [No Abstract]   [Full Text] [Related]  

  • 6. Intravitreal bevacizumab for parapapillary choroidal neovascularization due to exudative age-related macular degeneration.
    Jonas JB; Tao Y; Rensch F
    Acta Ophthalmol; 2011 Feb; 89(1):e105-7. PubMed ID: 20064119
    [No Abstract]   [Full Text] [Related]  

  • 7. Controversies in the treatment of wet age-related macular degeneration.
    Moreno SF; Paloma JB
    Am J Ophthalmol; 2008 May; 145(5):937; author reply 938. PubMed ID: 18435977
    [No Abstract]   [Full Text] [Related]  

  • 8. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration.
    Bom Aggio F; Eid Farah M; Melo GB
    Acta Ophthalmol Scand; 2006 Oct; 84(5):713-4. PubMed ID: 16965511
    [No Abstract]   [Full Text] [Related]  

  • 10. Retinal pigment epithelial tear after intravitreal bevacizumab injection.
    Shah CP; Hsu J; Garg SJ; Fischer DH; Kaiser R
    Am J Ophthalmol; 2006 Dec; 142(6):1070-2. PubMed ID: 17157598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.
    Bashshur ZF; Bazarbachi A; Schakal A; Haddad ZA; El Haibi CP; Noureddin BN
    Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
    Leydolt C; Michels S; Prager F; Garhoefer G; Georgopoulos M; Polak K; Schmidt-Erfurth U
    Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study.
    Costa RA; Jorge R; Calucci D; Cardillo JA; Melo LA; Scott IU
    Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4569-78. PubMed ID: 17003454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinal pigment epithelial tear following intravitreal bevacizumab injection for neovascular age-related macular degeneration.
    Gelisken F; Ziemssen F; Voelker M; Bartz-Schmidt KU
    Acta Ophthalmol Scand; 2006 Dec; 84(6):833-4. PubMed ID: 17083554
    [No Abstract]   [Full Text] [Related]  

  • 16. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study.
    Bashshur ZF; Haddad ZA; Schakal A; Jaafar RF; Saab M; Noureddin BN
    Am J Ophthalmol; 2008 Feb; 145(2):249-256. PubMed ID: 18067876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal bevacizumab.
    Lucas RS; McKee HD; Lee LR
    Ophthalmology; 2007 Feb; 114(2):400; author reply 400-1. PubMed ID: 17270701
    [No Abstract]   [Full Text] [Related]  

  • 18. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study.
    Chen CY; Wong TY; Heriot WJ
    Am J Ophthalmol; 2007 Mar; 143(3):510-2. PubMed ID: 17317398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment.
    El-Mollayess GM; Noureddine BN; Bashshur ZF
    Semin Ophthalmol; 2011 May; 26(3):69-76. PubMed ID: 21609219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
    Melamud A; Stinnett S; Fekrat S
    Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.